Immunoglobulin A (IgA) nephropathy is the most prevalent glomerulonephritis worldwide that does not have a specific treatment. Its pathogenesis is complex and not well understood, but there is ...

Studies have shown that lectin pathway activation contributes to multiple human diseases such as immunoglobulin A nephropathy (IgAN), hematopoietic stem-cell transplantation–associated ...

EP: 3. Pathogenesis of IgA Nephropathy: The 4-Hit Cascade, A Proliferation-Inducing Ligand (APRIL), and cytokines EP: 4. Diagnosing IgA Nephropathy EP: 5. Signs and Symptoms of IgA Nephropathy EP: 6.

Session ID: 2025-08-02:346be14421bd3cbc8a9b7fc Player Element ID: vjs_video_3 ...

Omeros Corporation (Nasdaq: OMER) today announced results of long-term follow-up from the Phase 2 clinical trial evaluating its MASP-2 inhibitor narso ...

TST004 is a humanized mAb targeting mannose-binding protein-associated serine protease 2 (MASP2) and designed to prevent the lectin pathway complement-mediated inflammation. Transcenta discovered ...

Specifically, TST004 inhibits mannose-binding protein-associated serine protease 2 (MASP2), which plays an important role in the lectin pathway activation that leads to diseases like IgA nephropathy.

IgA nephropathy is the most common primary glomerulopathy globally, with an estimated 120,000 to 180,000 cases in the U.S. alone, and accounts for up to 10 percent of all dialysis patients.

New 100-week data from the ongoing Phase I/II study of zigakibart, an investigational anti-APRIL monoclonal antibody, reinforce its potential as a disease-modifying treatment for IgA nephropathy ...

A first-in-class oral inhibitor of the alternative complement pathway that drives the pathogenesis of primary glomerulonephritis, iptacopan (LNP023, Novartis), is showing early promise as the ...

Immunoglobulin A (IgA) nephropathy is the most prevalent glomerulonephritis worldwide that does not have a specific treatment. Its pathogenesis is complex and not well understood, but there is ...

Omeros Corporation today announced results of long-term follow-up from the Phase 2 clinical trial evaluating its MASP-2 inhibitor narsoplimab in patients with IgA nephropathy. Treatment with ...